Valeriy Sabodash, MD
Neurology · Sarasota, FLNPI 1003008533
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Eisai Inc. accounts for 74.9% of it on its own, with 48 other manufacturers making up the rest. Among neurology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 529 payments — averaging $75.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$30K
- AstraZeneca$1K
- AbbVie$997
- Sanofi$834
- SK Life Science, Inc.$775
- Novartis$739
- plus $6K from 43 others
What the payments were for
- Consulting fees$4,46811%
- Speaking & faculty fees$20,98252%
- Travel & lodging$2,8287%
- Food & beverage$11,80229%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,079 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 47 | $1,049,502 |
| SolirisEculizumab | 12 | $638,729 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $275,029 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 21 | $228,085 |
| AustedoDeutetrabenazine | 29 | $176,422 |
| GocovriAmantadine Hcl | 55 | $156,680 |
| RytaryCarbidopa/Levodopa | 105 | $100,897 |
| BotoxOnabotulinumtoxina | 71 | $92,354 |
| NeuproRotigotine | 41 | $59,470 |
| RexultiBrexpiprazole | 37 | $52,408 |
| Aimovig AutoinjectorErenumab-Aooe | 54 | $51,825 |
| Emgality PenGalcanezumab-Gnlm | 59 | $49,281 |
| NuedextaDextromethorphan Hbr/Quinidine | 35 | $40,817 |
| Nurtec OdtRimegepant Sulfate | 28 | $35,745 |
| BriviactBrivaracetam | 15 | $34,825 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $45 | $1,049,50247 claims |
| AstraZenecaSoliris | $1,013 | $638,72912 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $387 | $176,42229 claims |
| MDD US Operations, LLCGocovri | $31 | $156,68055 claims |
| AbbVieBotox, Ubrelvy, Qulipta | $997 | $123,968104 claims |
| Amneal Pharmaceuticals LLCRytary | $243 | $100,897105 claims |
| UCB, Inc.Neupro, Briviact | $276 | $94,29556 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $166 | $52,40837 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $236 | $40,81735 claims |
| PfizerNurtec Odt | $14 | $35,74528 claims |
| SK Life Science, Inc.Xcopri | $775 | $9,98011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.
Other neurology in Sarasota
- Donald NegroskiSarasota$1.4M
- Julio CanteroSarasota$811K
- Victor KassiciehSarasota$318K
- Gregory HanesSarasota$255K
- Maurico ConchaSarasota$212K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.